US Patent Issued to BIONTECH, GENMAB on Sept. 23 for "Binding agents that bind OX40 (CD134) and method of use thereof to treat disease" (Dutch, German Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,421,319, issued on Sept. 23, was assigned to BIONTECH SE (Mainz, Germany) and GENMAB A/S (Valby, Denmark).

"Binding agents that bind OX40 (CD134) and method of use thereof to treat disease" was invented by Ugur Sahin (Mainz, Germany), Friederike Gieseke (Mainz, Germany), Isil Altintas (Utrecht, Netherlands), David Satijn (Utrecht, Netherlands) and Paul Parren (Utrecht, Netherlands).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. Th...